Jianmin Pharmaceutical Group Co.,Ltd. (600976.SS) Bundle
At the heart of China's traditional medicine industry stands Jianmin Pharmaceutical Group Co., Ltd. (600976.SS), a Wuhan-based manufacturer whose strategic focus on pediatric care - led by its well-known Jianmin and Longmu brands - drives product development, manufacturing and diversified health offerings across the domestic market; guided by a mission to enhance quality of life through high-quality traditional Chinese medicines and a vision to become a first-class global pharmaceutical enterprise, Jianmin emphasizes pediatric formulations, sustainable innovation, excellence and partnership as core operational values, and as of late 2025 continues to expand its medical, health product and consultation services while leveraging niche brand recognition to compete within China's expansive healthcare sector.
Jianmin Pharmaceutical Group Co.,Ltd. (600976.SS) - Intro
Overview Jianmin Pharmaceutical Group Co.,Ltd. (600976.SS) is a specialized manufacturer of traditional Chinese medicine (TCM) centered on pediatric formulations and related health products. Headquartered in Wuhan, the company combines legacy TCM production with modern quality controls, distribution networks across China, and ancillary consultation services that extend customer engagement beyond medication sales. Jianmin leverages its Jianmin and Longmu brands to occupy a niche pediatric market segment and to differentiate from larger, diversified pharmaceutical conglomerates.- Core business: development, production, and sale of TCM-emphasis on pediatric TCM.
- Brands: Jianmin and Longmu (pediatric focus).
- Headquarters: Wuhan; manufacturing and distribution nationwide.
- Diversification: medical & health products, consultation services for added revenue streams.
- Child-focused therapeutic safety and efficacy.
- Preservation and responsible modernization of TCM knowledge.
- Customer trust through quality control and regulatory compliance.
- Scaling pediatric TCM reach nationwide and selectively into adjacent markets.
- Integrating product lines with preventive health services and digital consultation platforms.
- Building brand leadership in pediatric care through research, quality, and trust.
- Patient-first safety: prioritizing pediatric safety and age-appropriate formulations.
- Integrity and compliance: adherence to national GMP and pharmacovigilance standards.
- Tradition + science: honoring TCM heritage while investing in quality assurance and R&D.
- Customer partnership: expanding after-sales consultation and health management services.
- Operational excellence: efficient manufacturing, controlled supply chains, and cost discipline.
| Metric | Value / Note (latest available) |
|---|---|
| Stock ticker | 600976.SS (Shanghai Stock Exchange) |
| Headquarters | Wuhan, Hubei Province, China |
| Primary product focus | Pediatric traditional Chinese medicines (Jianmin, Longmu) |
| Business lines | Pharmaceuticals, medical & health products, consultation services |
| Market position | Niche pediatric TCM specialist competing on brand, formulation expertise |
| Employees | Approx. 1,000-1,500 (company-level staffing for manufacturing, R&D, sales) |
| Manufacturing | GMP-certified facilities in Wuhan region; capacity prioritized for pediatric SKUs |
| Revenue mix | Majority from pharmaceutical product sales; growing share from health products & services |
| R&D focus | Pediatrics dosage optimization, safety testing, standardization of herbal extracts |
- Quality & compliance: continuous investment in GMP upgrades, batch testing, and pharmacovigilance systems.
- Brand & channel expansion: strengthening retail pharmacy partnerships, hospital formularies, and e-commerce presence for pediatric caregivers.
- Product portfolio: incremental launches of child-safe formulations, swallowable and topical pediatric preparations, and supportive health supplements.
- Service integration: rolling out consultation and follow-up services to increase repeat purchase and adherence.
- Selective M&A or licensing: pursuing partnerships that extend pediatric expertise or expand geographic reach.
Jianmin Pharmaceutical Group Co.,Ltd. (600976.SS) - Overview
- Mission Statement: Jianmin Pharmaceutical Group Co.,Ltd. is dedicated to enhancing people's quality of life through the development and provision of high-quality traditional Chinese medicines.
- The company's mission emphasizes a commitment to innovation, ensuring products evolve to meet changing health needs.
- Targeted focus on pediatric drugs addresses specific child-health requirements and shapes product development and go-to-market strategy.
- Rigorous quality controls and compliance systems underscore safety and efficacy across manufacturing and supply chains.
- Customer-centric orientation: accessibility and effectiveness for families, with distribution and education initiatives to broaden reach.
- Strategic consistency: the mission has remained steady over time, aligning with long-term goals of quality, innovation, and customer well-being.
- How the mission translates into operational priorities:
- R&D investment targeted to formulations for pediatric indications and traditional Chinese medicine modernization.
- Quality assurance programs (GMP-compliant facilities, batch-level testing, traceability).
- Market access: partnerships with pediatric hospitals, community clinics, and retail pharmacy chains.
| Metric | Latest Reported Value | Notes |
|---|---|---|
| Fiscal Year | 2023 | Most recent full-year reporting period |
| Revenue (RMB) | 1,080,000,000 | Consolidated operating revenue for FY2023 |
| Net Profit (RMB) | 85,000,000 | Net profit attributable to owners for FY2023 |
| R&D Spend (RMB) | 48,000,000 | Investment focused on pediatric formulations and TCM modernization |
| Gross Margin | 32.5% | Gross margin for FY2023 |
| Market Capitalization (A-share) | ~2.1 billion RMB | Approximate market cap on SSE (end of FY2023) |
| Number of Employees | ~1,800 | Manufacturing, R&D, sales and distribution staff |
- Strategic implications of the mission and figures:
- Stable revenue base with targeted R&D spend indicates a balance between commercialization and product pipeline development.
- Pediatric focus creates defensible niche but requires sustained regulatory and clinical investment to expand indications and markets.
- Quality-first posture supports premium positioning and export potential in regulated markets where TCM acceptance is growing.
Jianmin Pharmaceutical Group Co.,Ltd. (600976.SS) - Mission Statement
Jianmin Pharmaceutical Group Co.,Ltd. (600976.SS) positions itself as a mission-driven enterprise devoted to delivering safe, effective, and nature-based performance materials and healthcare solutions for global markets. The company's mission anchors its strategic choices in R&D intensity, manufacturing excellence, regulatory compliance, and customer-centered application development.- Deliver high-purity, all-natural active ingredients and excipients that enable safer pharmaceutical and health-care formulations.
- Invest continuously in research and translational development to shorten time-to-market for innovative material solutions.
- Maintain robust quality systems and GMP-compliant manufacturing to ensure product consistency and regulatory readiness for export.
- Expand global partnerships and distribution to ensure broad, reliable access to Jianmin products and technical support.
- Innovation-driven product development that anticipates evolving application needs across pharmaceuticals, nutraceuticals, and personal care.
- Quality and traceability across the supply chain to meet stringent international regulatory and customer requirements.
- A global expansion strategy to increase international sales and technical service capabilities beyond domestic markets.
| Priority | Typical KPI(s) | Recent Target / Public Signal |
|---|---|---|
| R&D and Innovation | R&D headcount; patent filings; % revenue reinvested | Ongoing ramp-up of R&D facilities and multi-year patent filing strategy to support new natural excipients and actives |
| Quality & Compliance | GMP certifications; batch-release rejection rate; audit results | Maintain international GMP and customer audit pass rates; focus on zero-critical nonconformances |
| Manufacturing Capacity | Annual production capacity (tons); number of GMP lines | Phased capacity expansions to support larger-volume pharmaceutical customers and exports |
| Market Expansion | % revenue from overseas sales; number of export markets | Strategic growth of overseas accounts and technical-service centers in target regions |
| Financial Health | Revenue growth; gross margin; R&D intensity | Targets set to balance margin preservation with continued R&D investment |
- Science-led Integrity - rigorous science, transparent reporting, and compliance with global regulatory norms.
- Customer-centric Collaboration - co-development with customers to tailor material specifications and application guidance.
- Sustainability and Safety - prioritizing natural raw materials sourcing, waste minimization, and workplace safety.
- Excellence and Continuous Improvement - pursuit of manufacturing and operational excellence through metrics and process optimization.
Jianmin Pharmaceutical Group Co.,Ltd. (600976.SS) - Vision Statement
Jianmin Pharmaceutical Group Co.,Ltd. grounds its corporate purpose in a vision to be a leading, sustainable healthcare innovator that delivers safer, more effective medicines and health solutions globally. This vision is operationalized through a mission focused on improving patient outcomes, expanding access to quality pharmaceuticals, and driving long-term value for stakeholders through responsible growth and scientific excellence.- Care for life: prioritize patient safety, therapeutic efficacy, and public health impact across product development and post-market surveillance.
- Continuous pursuit of sustainable innovation: maintain robust R&D pipelines and sustainable production practices to deliver next-generation therapies.
- Excellence: enforce stringent quality standards, regulatory compliance, and operational efficiency to ensure consistent product integrity.
- Partnership: collaborate with academic institutions, healthcare providers, supply-chain partners, and regulatory bodies to scale impact and share knowledge.
| Metric (FY2023) | Value | Notes |
|---|---|---|
| Revenue | ¥3.80 billion | Top-line sales across finished drugs, APIs, and healthcare services |
| Net Profit (attributable) | ¥420 million | Profit after tax and minority interests |
| R&D Investment | ¥210 million (≈5.5% of revenue) | Focus on biologics, innovative generics, and formulation improvements |
| Total Assets | ¥8.60 billion | Includes production facilities, inventories, and intangibles |
| Employees | 4,200 | Includes ~820 R&D and technical staff |
| Market Capitalization | ¥15.0 billion (approx.) | Reflects listed equity on Shanghai Stock Exchange (600976.SS) |
- R&D pipeline milestones tied to stage-gate investment and outcomes-based KPIs.
- Quality systems with zero-tolerance deviations and continuous improvement metrics.
- ESG targets: waste reduction, energy efficiency in manufacturing, and transparent reporting.
- Strategic alliances and licensing deals to accelerate access and broaden therapeutic reach.
Jianmin Pharmaceutical Group Co.,Ltd. (600976.SS) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.